The Global Anti Epilepsy Drugs industry is projected to grow from USD 11.03 Billion in 2024 to USD 15.68 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.30% during the forecast period (2024 - 2032). Anti-epileptic drugs, as a prominent market inclusion, are prescribed for patients who are adversely suffering from seizures.
The major symptom that is related to epilepsy is repeated seizures, which are known as sudden bursts of electrical activity in the brain, and that there is an inclusion of the temporarily affects the functioning of the brain. Some seizures that appear cause the body to jerk and shake, while others are likely to cause many problems such as loss of awareness or unusual sensations. Anti-epileptic drugs that are known as AEDs include a diverse class of solutions like medications that are increasingly being used for different conditions apart from epilepsy such as migraine prophylaxis, and others like neuropathic pain, and bipolar disorder.
The drugs that are prescribed for anti-epileptics are categorized into three different kinds of generations. Each generation denotes a different kind of specification. The first-generation drugs include some like Bromide, Phenobarbital, Primidone, Carbamazepine amongst many others. They lie between “1857-1970”, followed by the second generation drugs including many like Felbamate, Lamotrigine, Levetiracetam, amongst rest of the others lies between “1989-2007” and the third-generation drugs that include Lacosamide, Eslicarbazepine Acetate, Clobazam.
Over 70 million people worldwide suffer from epilepsy, a common neurological illness. Epilepsy is not a single illness or syndrome, even though there are numerous varieties of epileptic seizures, including convulsive, focal, non-convulsive, and generalized seizures, among others. Despite the market's accessibility to AEDs, one-third of people experience drug intolerance. The producers are making several efforts to lessen this issue. The creation of target-specific medications about the neurobiology of the medical condition has recently been the focus of R&D. AEDs are being introduced under pressure from the market players due to the increasing prevalence of epilepsy and the desire for therapeutically effective drugs. The increasing number of pharmaceuticals that regulatory authorities are expected to approve will likely boost the expansion of the international market for antiepileptic treatments.
Rising epilepsy prevalence is predicted to fuel market expansion in places like Europe over the projection period. The market is also predicted to develop throughout the forecast period due to increased inorganic growth tactics, such as collaborations between large companies. Instead, it is a wide range of ailments. The primary therapy for this illness, which is characterized by recurrent seizures, is antiepileptic drug (AED) therapy. About two-thirds of persons with epilepsy can control their seizures if properly diagnosed and treated. The path for the opportunistic expansion of the global market for antiepileptic medications will be established by a sizable clinical pipeline and investigational research to develop innovative antiepileptic drugs for children and geriatric patients.
Sudden behavioral changes, intense emotional discomfort, and unconsciousness are symptoms of epilepsy in patients. Leading industry participants are currently concentrating on the release of drugs with fewer adverse effects for patients. Additionally, they are concentrating on improving the medications' capacity to control epilepsy symptoms successfully. Although epilepsy, seizures, and other chronic illnesses are becoming more common in emerging nations, some factors prevent the market for antiepileptic medications from expanding. The sharp increase in drug supply scarcity is one of the main factors limiting market expansion. Due to a lack of medications at the pharmacies, patients are gathering these medications. Investigations of the worldwide medication supply system have been alarmed by this.
In January 2024, Akumentis Healthcare announced the launch of a pharmaceutical product specifically designed for the management of epilepsy. Clasepi, a prescription cannabidiol (CBD) developed by a Mumbai-based business, has been approved by the Drug Controller General of India (DCGI). It is specifically designed to treat seizures associated with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, or Tuberous Sclerosis Complex (TSC) in individuals who are at least 1 year old. Clasepi's effectiveness in lowering seizures has been proved in clinical research, particularly in circumstances when traditional anti-seizure drugs have been unsuccessful. Our dedication to creating innovative treatments that properly alleviate the intricacies of these ailments is what drives us. As per the World Health Organisation (WHO), epilepsy is a significant component of the overall global disease burden, impacting around 50 million individuals globally, with 20 percent of patients living in India.
News:
Epilepsy patients are 2.5 times more likely than people in general to receive a Parkinson's disease diagnosis, according to British researchers. Now, a study by several experts raises the possibility that using specific antiepileptic drugs may contribute to the elevated risk.
COVID 19 Analysis
The sudden outbreak of the coronavirus pandemic and its facilities has imposed the global governments to impose lockdowns in various countries across the globe that have impacted the financial status of business across all sectors. The private healthcare sector of the antiepilepsy drugs market is emerging as one of the sectors which have been majorly impacted by the outbreak of the COVID-19 pandemic. The imposed lockdown in various countries due to the COVID-19 pandemic has created an economic rift and burden on the functioning of the private healthcare sector. According to the Indian Journal of Medical Sciences published a report in 2020, the outbreak of the COVID-19 pandemic has affected the conduction of clinical trials of vaccine and medicine due to the unavailability of trial site staff, followed by the restrictions imposed for traveling, investigational product availability, and many others.
According to the information circulated by the National Center for Biotechnology Information (NCBI) in its published report on April 29, 2020, many clinical trials suspended the trial enrollment, and aim to minimize the risk of contracting COVID-19. This act has led to cause a delay in the activation of a new clinical trial. Moreover, many companies have already reported having missed the follow-up for the patients already in the middle of the trials. Product development has experienced disruptions to focus on the adjustments to remote-work environments and lab capacity has also apparently reduced. The process of the clinical trials is also being severely affected with disruptions in both new enrollments and in keeping the existing patients on therapies. According to the information stated by clinicaltrial.gov, as of April 2020, there were more than 2,850 trials conducted and approximately 900,000 patients enrolled at trial sites in various regions and especially the ones that were in partial or complete lockdown due to COVID-19 restrictions. While the research and development, labs are currently operating at below 50% of the normal capacity across the globe.
Drivers
There are many factors that are assisting the market growth during the forecast period. including the rising number of collaborations by key players in the antiepilepsy drugs market. For instance, in May 2021, Epilepsy Foundation, which is a U.S.-based non-profit national foundation, entered into a collaboration with another prominent player - Eisai Inc., which is a Japanese pharmaceutical company, for the development of the Epilepsy Digital Experience Navigator (EDEN). It is a platform designed to empower people with epilepsy, their caregivers, as well as, clinicians, to use data to better understand and improve the epilepsy journey.
Restraints
However, the global growth of the antiepilepsy drugs market is expected to be hampered over the forecast period that will be ending in 2027, owing to the adoption of alternative treatments for children with epilepsy. Complementary and alternative medicine (CAM), which include the ketogenic diet, modified Atkins diet (MAD), followed by the low glycemic index treatment (LGIT) that are widely used for the treatment of epilepsy among children, in addition to the use of AEDs. For instance, according to the Clinical Nutrition Research which is a research study conducted to examine the consumption of nutritional supplements used in various treatments in 2016, as a part of the historic forecast period that had ended in 2018, around 30% of the children suffering from uncontrolled epileptic seizures were untreated worldwide, where a ketogenic diet (KD) could be potentially used in the form of an alternative medical treatment for these children, these factors are expected to restrain the global antiepilepsy drugs market growth for the forecast period.
Furthermore, there are prominent steps undertaken by the market key players followed by the fact that they are focused on gaining approvals from regulatory bodies, this is expected to drive the growth of the antiepilepsy drugs market based on the projections for the ongoing forecast period. For instance, in July 2019, a prominent market company - Pfizer, Inc. had announced the approval of the U.S Food and Drug Administration for the first generics of Lyrica (pregabalin) as adjunctive therapy for the treatment of partial-onset seizures in patients that belong to the age group of 17 years of age and older.
The antiepilepsy drugs market share is segmented to meet the rising needs of the global target audience.
The drug type segment is segmented into two broad categories, namely first and second-generation antiepileptic drugs. Phenytoin, carbamazepine, oxcarbazepine, and valproate are a part of the first generation class, and it dominates the overall antiepilepsy drugs market. From the second-generation drugs, some inclusions are zonisamide, levetiracetam, and lacosamide. These are gaining immense popularity due to their tolerability and high efficacy.
Geographically, the global antiepileptic drugs market is segmented as North America, Europe, Asia-Pacific, and LAMEA.
News:
The Drug Controller General of India (DCGI) has authorized Perampanel Oral Suspension, according to an announcement by Akums, a Contract Development and Manufacturing Organization (CDMO). According to a press release from the company, this approval enables Perampanel Oral Suspension to be used as adjunctive therapy in the management of primary generalized tonic-clonic (PGTC) seizures and partial-onset seizures (POS) in patients with epilepsy who are 12 years of age and older in the nation.
The United States is expected to emerge as the largest epilepsy drug market owing to the presence of better healthcare infrastructure followed by the rising cases of epilepsy. As per the Epilepsy Foundation of Michigan, epilepsy is known as the fourth most common neurological disorder in the United States after migraine, stroke, and Alzheimer’s disease. About one percent of the total number of Americans have some form of epilepsy and nearly four percent of that 1 in every 26 will develop epilepsy at some point in their lives. The number of Americans who have epilepsy is greater than the number who have multiple sclerosis, and other problems like Parkinson’s disease and cerebral palsy combined. Thus, there is a rising demand for effective treatment in the US region which is expected to boost the growth of the epilepsy drug market.
Furthermore, there are various organizations that are functioning and making awareness about epilepsy in the United States.
The key players operating in the global anti-epileptic drugs market are:
The rise in the generic competition for antiepileptics is due to the patent expiration of major brands and in the future, it is likely to be responsible for down pricing of branded drugs.
Lyrica was known to be the largest selling antiepileptic brand owing to its highly efficacious nature. Others like Retigabine and perampanel are recently approved antiepileptics, which act through new molecular targets.
In May 2018, UCB announced that the United States Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for its newest anti-epileptic drug (AED) BRIVIACT (brivaracetam) CV oral formulations.
The global antiepilepsy market report has been prepared to provide proper market insights followed by the dynamics that have a hand at depicting the growth and revenue scale of the global market for the ongoing forecast period. The report helps to form decisions of the market investors and also, understand the rising competition amongst the market segments and players functional in different parts across the participating regions, globally.
| Report Attribute/Metric | Details |
| Â Â Market Size | Â Â USD 15.68 billion |
| Â Â CAGR | Â 5.30% |
| Â Â Base Year | Â Â 2023 |
| Â Â Forecast Period | Â Â 2024-2032 |
| Â Â Historical Data | Â Â 2021 |
| Â Â Forecast Units | Â Â Value (USD Billion) |
| Â Â Report Coverage | Â Â Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Â Â Segments Covered | Â Â Types of seizures, Generation |
| Â Â Geographies Covered | Â Â North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Â Â Key Vendors | Â Â Pfizer, Inc., Johnson & Johnson, UCB Pharma Ltd., Abbott Laboratories, GlaxoSmithKline plc, Novartis International AG, Sanofi S.A., Shire Pharmaceuticals Limited and Cephalon Inc. |
| Â Â Key Market Opportunities | Â Â New product launches and R&D Amongst major key Players |
|   Key Market Drivers | · Development of better tolerated third generation drugs· Increasing screening of patients, penetration and availability of drugs· Growth of geriatrics as they are affected more by epilepsy |
Frequently Asked Questions (FAQ) :
The antiepilepsy drugs market is projected grow at approximately 5.30% CAGR during the assessment period (2024-2032).
The valuation of the Antiepilepsy drugs market is estimated to increase to USD 15.68 BN by the end of 2032.
Rising per capita healthcare expenditure and increasing R&D for the therapeutic procedures of the condition are major drivers of the antiepilepsy drugs market.
North America holds the largest share in the antiepilepsy drugs market, followed by Europe and the Asia Pacific, respectively.
Johnson & Johnson, Pfizer, Inc., UCB Pharma Ltd., GlaxoSmithKline plc, Abbott, Novartis AG, Shire Pharmaceuticals Limited, Sanofi, and Cephalon Inc., are some of the major players operating in the antiepilepsy drugs market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
